Previously, Taniguchi et. al. reported that in hematologic malignancies ARNTL was transcriptionally silenced by the hypermethylation of its promoter CpG island.30 TCGA data showed that the expression of ARNTL was significantly lower in most solid tumors than in nontumor tissues; in addition, hypermethylation of ARNTL was also observed in PRAD (Figure 2A) and STAD, while the methylation status of ARNTL in other cancers was not available. This evidence concerns the gene BMAL1 and hematologic disorder.